BidaskClub upgraded shares of LeMaitre Vascular (NASDAQ:LMAT) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday, January 16th.
A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered LeMaitre Vascular from a buy rating to a hold rating in a research note on Thursday, September 28th. Canaccord Genuity lowered their price objective on LeMaitre Vascular from $30.00 to $29.00 and set a hold rating for the company in a research note on Friday, October 27th. First Analysis lowered LeMaitre Vascular from an overweight rating to an equal weight rating and set a $34.00 price objective for the company. in a research note on Friday, October 27th. Benchmark lowered LeMaitre Vascular from a buy rating to a hold rating in a research report on Friday, October 27th. Finally, Stifel Nicolaus reiterated a buy rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $32.20.
LeMaitre Vascular (NASDAQ LMAT) opened at $34.13 on Tuesday. The company has a market capitalization of $657.51, a PE ratio of 44.32, a PEG ratio of 2.63 and a beta of 0.53. LeMaitre Vascular has a twelve month low of $19.82 and a twelve month high of $39.88.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.